Skip to main content
EJNMMI Research
Fig. 1 | EJNMMI Research

Fig. 1

From: Early response monitoring of neoadjuvant chemotherapy using [18F]FDG PET can predict the clinical outcome of extremity osteosarcoma

Fig. 1

ROC curves of SUV2, Δ%SUV01, and Δ%SUV02 using [18F]FDG PET for predicting event-free survival of osteosarcoma. SUV2 is the SUVmax of the primary tumor after completion of neoadjuvant chemotherapy (a). Δ%SUV01 is the percentage change in SUVmax between baseline and interim of [18F]FDG PET (b). Δ%SUV02 is the percentage change in SUVmax between baseline and posttherapy of [18F]FDG PET/CT (c)

Back to article page